Thursday, January 31, 2008

Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet

THOUSAND OAKS, Calif., Jan 31, 2008 – Amgen Inc. (NASDAQ: AMGN) today announced data from two Phase 3 studies which evaluated the administration of Nplate(TM) (romiplostim) on increasing and sustaining platelet counts in both splenectomized (spleen removed) and non-splenectomized patients with chronic Immune Thrombocytopenic Purpura (ITP). The data will be published in the Feb. 2, 2008, issue of The Lancet.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Monday, January 28, 2008

Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology

THOUSAND OAKS, Calif. – Jan. 28, 2008 – Amgen (NASDAQ:AMGN) issued the following statement on the publication of an Aranesp(R) (darbepoetin alfa) manuscript in the January 28, 2008, online issue of the Journal of Clinical Oncology. Amgen anticipates this manuscript will be available in the March 1, 2008, print edition.

Read the rest of this entry

Posted in Press Releases, Product News

Sunday, January 27, 2008

Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy

Emerging Data From Two Phase 3 Trials Exploring Vectibix in Earlier Lines of Colorectal Cancer Treatment

ORLANDO, Fla. – Jan. 27, 2008 – Amgen (NASDAQ: AMGN) today announced interim pooled, blinded safety data from two Phase 3 trials examining Vectibix(TM) (panitumumab) in combination with chemotherapy in first- and second-lines of metastatic colorectal cancer (mCRC) treatment. The respective independent Data Monitoring Committee’s reviews of the pooled, or combined, safety data from both arms of these randomized, multi-center trials endorsed the continuation of these studies per protocol. These interim data were presented today at the 2008 Gastrointestinal Cancers Symposium (ASCO GI) in Orlando, Fla.

Read the rest of this entry

Posted in Press Releases, Product News

Thursday, January 24, 2008

KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients

Data Presented at ASCO GI Further Validate KRAS as a Potential Patient Selection Biomarker for Vectibix Monotherapy

ORLANDO, Fla., Jan 24, 2008 – Amgen (NASDAQ: AMGN) today announced the results of a biomarker analysis which indicated that in metastatic colorectal cancer (mCRC) patients who have failed all other chemotherapeutic regimens, the efficacy of Vectibix(TM) (panitumumab) monotherapy is confined to patients with non-mutated (wild-type) KRAS tumors. Specifically, in patients with non-mutated KRAS tumors, Vectibix significantly increased progression-free survival (PFS) and had an impact on quality of life (QoL) and disease-related symptoms, compared to best supportive care (BSC) alone. These data will be presented at an oral presentation on Saturday, January 26th at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).

Read the rest of this entry

Posted in Press Releases, Product News

Thursday, January 24, 2008

Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))

THOUSAND OAKS, Calif., Jan 24, 2008 – Amgen (NASDAQ:AMGN) today announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women with low bone mineral density. The study met primary and all secondary endpoints.

Read the rest of this entry

Posted in Press Releases, Pipeline News